



# LEADER

Liraglutide Effect and Action in Diabetes:  
Evaluation of cardiovascular outcome Results

## Victoza® demonstrated CV risk reduction in the LEADER trial<sup>1</sup>

### Topline results<sup>1</sup>



Relative risk reduction in  
major adverse CV events

Victoza® demonstrated superiority  
with a significant reduction in  
cardiovascular (CV) risk



The safety profile of Victoza®  
in LEADER was consistent with  
previous liraglutide trials

### LEADER facts<sup>1</sup>

LEADER investigated the CV safety of Victoza® in adults with type 2 diabetes  
and high CV risk



9,340  
patients



410  
trial sites



32  
countries



Followed for  
3.5–5 years

#### Reference:

1. Marso SP, et al; Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. June 13, 2016.

